Join to View Full Profile
55 Fruit StBoston, MA 02114
Phone+1 617-726-1728
Dr. Arnold is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Steven Arnold is a neurologist and psychiatrist in Boston, MA and is affiliated with Massachusetts General Hospital. He received his medical degree from Boston University School of Medicine and has been in practice 33 years. He specializes in neurodegenerative diseases and dementia & and is experienced in alzheimer's disease, behavioral neurology / neuropsychiatry, and geriatrics / dementia.
Education & Training
University of Iowa Health Care Medical CenterResidency, Neurology, 1987 - 1990
New York Presbyterian Hospital (Columbia Campus)/New York State Psychiatric InstituteResidency, Psychiatry, 1984 - 1987
Icahn School of Medicine at Mount Sinai/Morningside/WestInternship, Internal Medicine, 1983 - 1984
Boston University School of MedicineClass of 1983
Certifications & Licensure
MA State Medical License 2015 - 2028
ME State Medical License 2021 - 2026
RI State Medical License 2021 - 2022
PA State Medical License 1990 - 2016
IA State Medical License 1987 - 1992
American Board of Psychiatry and Neurology Neurology- American Board of Psychiatry and Neurology Psychiatry
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease. Start of enrollment: 2010 Dec 01
- Effect of Insulin Sensitizer Metformin on AD Biomarkers Start of enrollment: 2013 Jan 01
- A Pilot of Methylphenidate in Mild Cognitive Impairment and Dementia Participants. Start of enrollment: 2019 Nov 01
Publications & Presentations
PubMed
- Phosphorylated Tau at Threonine 181 Is Elevated in Amyotrophic Lateral Sclerosis Plasma.Tiziana Petrozziello, Evan Mizerak, Aparna Krishnamoorthy, Rachel A Donahue, Ayleen L Castillo Torres
Muscle & Nerve. 2026-07-01 - Real-world comparison of brain [F]FDG-PET imaging with CSF Alzheimer's disease biomarkers in a tertiary memory clinic setting.Neus Rabaneda-Lombarte, João Pedro Ferrari-Souza, Johanna Celedon, Eduardo R Zimmer, Bradford C Dickerson
Eclinicalmedicine. 2026-05-01 - Combining p-tau217 and digital cognitive testing to predict cognitive decline.Hairin Kim, Daniel Soberanes, Roos J Jutten, Mark A Dubbelman, Hyun-Sik Yang
Alzheimer's & Dementia. 2026-04-01
Journal Articles
- Neurodegenerative Disease Concomitant Proteinopathies Are Prevalent, Age-Related and APOE4-AssociatedDavid Wolk, Steven E Arnold, Edward B Lee, David J Irwin, Leo McCluskey, Howard I Hurtig, Lauren Elman, Bruce Miller, Murray Grossman, John E Duda, John Q Trojanowski,..., Brain
Press Mentions
Amylyx Touts ‘Encouraging’ Phase 2 Alzheimer’s Trial DataAugust 15th, 2024- Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer’s Disease Pathology and NeurodegenerationAugust 12th, 2024
- Inside the Hunt for an Alzheimer’s Disease VaccineDecember 16th, 2022
Grant Support
- Targeted Proteomics Of Resilient Cognition In AgingNational Institute On Aging2011–2012
- Neurobiology Of Dysbindin In Schizophrenia And Sdy MouseNational Institute Of Mental Health2005–2008
- Plasticity In Stimulus Encoding Circuits In SchizophreniaNational Institute Of Mental Health2001–2002
- Olfactory Neurodevelopmental Pathology In SchizophreniaNational Institute Of Mental Health2000–2002
- MAP2 And The Neuronal Cytoskeleton In SchizophreniaNational Institute Of Mental Health1999–2002
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
